RxDoctor Payments Data

Shelli Farhadian, MD

Infectious Disease · New Haven, CTNPI 1104191311

Payments from drug & device makers

What this record shows

That places this record below the midpoint for infectious disease clinicians in CT, where the typical reported total is $181.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$334,394in research payments, 2019–2025

Across 3 payments — averaging $111,465 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$334K

How this compares

$0 in reported general payments places this provider in the 20th percentile of 159 infectious disease providers in Connecticut.

See all infectious disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$6,396
Medicare patients
23
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala15$62,735
Atorvastatin Calcium13$251

Paid to pharmacies, not to this prescriber.

Other infectious disease in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →